Literature DB >> 28589576

Editorial: non-alcoholic fatty liver disease-a pandemic in need of novel treatments and endpoints.

V Ajmera1, R Loomba2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28589576      PMCID： PMC5501982          DOI： 10.1111/apt.14081

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  10 in total

Review 1.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

2.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

3.  Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.

Authors:  Janki Patel; Ricki Bettencourt; Jeffrey Cui; Joanie Salotti; Jonathan Hooker; Archana Bhatt; Carolyn Hernandez; Phirum Nguyen; Hamed Aryafar; Mark Valasek; William Haufe; Catherine Hooker; Lisa Richards; Claude B Sirlin; Rohit Loomba
Journal:  Therap Adv Gastroenterol       Date:  2016-07-05       Impact factor: 4.409

4.  Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.

Authors:  W Kim; B G Kim; J S Lee; C K Lee; J E Yeon; M S Chang; J H Kim; H Kim; S Yi; J Lee; J-Y Cho; S G Kim; J-H Lee; Y J Kim
Journal:  Aliment Pharmacol Ther       Date:  2017-02-22       Impact factor: 8.171

5.  Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.

Authors:  Rieko Shimozono; Yoshiji Asaoka; Yoshitaka Yoshizawa; Takumi Aoki; Hidetoshi Noda; Masateru Yamada; Mie Kaino; Hidenori Mochizuki
Journal:  Mol Pharmacol       Date:  2013-04-16       Impact factor: 4.436

Review 6.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

7.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.

Authors:  Mazen Noureddin; Jessica Lam; Michael R Peterson; Michael Middleton; Gavin Hamilton; Thuy-Anh Le; Ricki Bettencourt; Chris Changchien; David A Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

8.  Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.

Authors:  Thuy-Anh Le; Joshua Chen; Christopher Changchien; Michael R Peterson; Yuko Kono; Heather Patton; Benjamin L Cohen; David Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

9.  Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits.

Authors:  Anwar Dudekula; Vikrant Rachakonda; Beebijan Shaik; Jaideep Behari
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

10.  Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).

Authors:  Rohit Loomba; Claude B Sirlin; Brandon Ang; Ricki Bettencourt; Rashmi Jain; Joanie Salotti; Linda Soaft; Jonathan Hooker; Yuko Kono; Archana Bhatt; Laura Hernandez; Phirum Nguyen; Mazen Noureddin; William Haufe; Catherine Hooker; Meng Yin; Richard Ehman; Grace Y Lin; Mark A Valasek; David A Brenner; Lisa Richards
Journal:  Hepatology       Date:  2015-02-27       Impact factor: 17.425
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.